Alios
BioPharma, Inc. today announced the discovery of first-in-class
anti-RSV nucleoside analogs that will be developed for the treatment
of acute RSV infection. Data from the company's discovery and
preclinical studies were presented at the 8th Annual Respiratory
Syncytial Virus Symposium held in Santa Fe, New Mexico from September
27-30. The company said the compounds were discovered by screening
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in